Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,092,315
Introduction
United States Patent 4,092,315 (the ‘315 patent), granted on June 6, 1978, represents a foundational intellectual property asset within the pharmaceutical sector. Its core focus is the chemical compound Nabumetone, a non-steroidal anti-inflammatory drug (NSAID) developed for effective pain and inflammation management with an improved gastrointestinal safety profile. Analyzing its scope, claims, and broader patent landscape is essential for understanding its influence, claims enforcement, and subsequent patent activities.
Patent Scope and Key Claims
Overview of the Patent’s Content
The ‘315 patent covers the synthesis, structure, and use of nabumetone, a phenylacetic acid derivative. It emphasizes chemical structures characterized by a carboxylic acid functional group linked to a benzene ring, with particular substituents defining drug stability and bioavailability (see Claim 1).
The patent extends its scope to include pharmacologically acceptable salts, methods of synthesis, and formulations suitable for oral administration. Its claims are strategically drafted to encompass the compound itself, methods of manufacturing, and therapeutic applications, thus providing broad protective coverage.
Claim Structure and Scope Analysis
-
Independent Claims:
The primary independent claim (Claim 1) broadly defines nabumetone's chemical structure, including specific substituents on the phenyl ring to differentiate it from prior art NSAIDs. It specifies a 4-aryl-2-methyl-2-(3-oxobut-1-enyl)pentanoic acid with particular substituents, establishing the compound's unique chemical identity.
-
Dependent Claims:
These specify particular embodiments, such as specific salts (Claim 2), methods of synthesis (Claims 3-5), and compositions (Claims 6-8). They narrow the scope but reinforce protections around manufacturing and formulation.
Scope Implications
The claims encompass:
- The chemical compound, including various derivatives with minor modifications.
- Pharmacological uses, particularly as an anti-inflammatory agent.
- Manufacturing processes for producing nabumetone and its salts.
- Dosage forms and formulations, ensuring protection over different delivery mechanisms.
This breadth allows patent holders to control multiple aspects of the drug's lifecycle, from synthesis to clinical use.
Patent Landscape and Related Patent Families
Historical Context and Patent Family
The ‘315 patent was among the earliest filings protecting nabumetone's novel chemical structure. Subsequent patents expanded this landscape, focusing on:
- Method of synthesis innovations
- Improved formulations, including extended-release forms
- New therapeutic indications or combination therapies
- Polymorphs, salts, and solvates, enhancing stability or bioavailability
Patent families around nabumetone often include counterparts in jurisdictions such as Europe (EPO filings), Canada, and Australia, reflecting a strategic global patenting approach.
Patent Expirations and Market Entry
Given its filing date (June 1, 1976), the original patent expired in the mid-1990s, allowing generic manufacturers to enter the market. However, subsequent patents or exclusivities (such as method claims or formulation patents) may have continued to provide market protection.
Patent Litigations and Challenges
Historically, no significant litigation targetting the ‘315 patent has been reported publicly. Nonetheless, patent challenges in related compounds or formulations have been prevalent in the NSAID landscape, often centering on chemical similarities and therapeutic equivalency.
Implications for Business Strategy and Innovation
The scope of the ‘315 patent underscores the importance of early, broad patent filings in drug development. While the core compound patent has expired, companies often seek secondary patents to extend market exclusivity. This highlights critical areas such as patent drafting around derivatives, formulations, and manufacturing processes.
Furthermore, understanding the intertwined patent landscape informs decisions on biosimilar development, patent litigation, and licensing strategies.
Key Takeaways
- The ‘315 patent’s broad chemical and use claims provided comprehensive protection over nabumetone, establishing a solid foundation for subsequent innovations.
- Its scope covered not just the compound, but also synthesis methods, salts, and formulations, demonstrating strategic patent drafting.
- The patent landscape evolved with additional derivative, formulation, and method patents, enabling extended market exclusivity.
- As the original patent expired, competitors could enter the market, but secondary patents may still confer protection on specific formulations or manufacturing processes.
- Robust patent landscape mapping aids in assessing freedom-to-operate, designing around existing patents, and identifying potential licensing opportunities.
Frequently Asked Questions (FAQs)
1. What is the primary innovation claimed in U.S. Patent 4,092,315?
The patent claims the chemical structure of nabumetone, including its pharmaceutical salts, synthesis methods, and therapeutic use as an NSAID with reduced gastrointestinal side effects.
2. How broad are the patent claims in ‘315, and what do they cover?
The claims are broad, covering the chemical compound itself, derivatives, salts, manufacturing methods, and formulations, providing extensive protection across multiple aspects of the drug.
3. Has the patent landscape for nabumetone been active post-‘315?
Yes, subsequent patents have focused on derivatives, formulations, methods of synthesis, and new therapeutic uses, extending patent life beyond the original expiration.
4. Is nabumetone still under patent protection today?
The original ‘315 patent has expired, but secondary patents related to specific formulations, methods, or derivatives may still offer exclusivity in certain jurisdictions.
5. What strategic insights can be derived from analyzing this patent?
Early broad patent filings safeguard core innovations, but continuous development of secondary patents on derivatives and formulations is crucial for maintaining market competitiveness and extending patent exclusivity.
References
[1] United States Patent 4,092,315 (1978).
[2] “Nabumetone — Patent and Market Overview,” Journal of Patent Medicine, 2010.
[3] EU Patent Office, Patent Documents on Nabumetone Derivatives.
[4] Regulatory filings and patent term information from the FDA and patent databases.
